PAVmed Inc. (NASDAQ:PAVM) is scheduled to be issuing its n/a quarterly earnings data after the market closes on Thursday, November 16th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. On average, analysts expect PAVmed to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

PAVmed Inc. (NASDAQ:PAVM) opened at $3.90 on Wednesday. PAVmed Inc. has a 52-week low of $2.54 and a 52-week high of $10.72.

TRADEMARK VIOLATION WARNING: “PAVmed Inc. (PAVM) Set to Announce Quarterly Earnings on Thursday” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/pavmed-inc-pavm-set-to-announce-quarterly-earnings-on-thursday/1703546.html.

Several research analysts have weighed in on PAVM shares. Dawson James reiterated a “buy” rating and issued a $10.10 price target on shares of PAVmed in a research report on Tuesday, September 5th. ValuEngine upgraded shares of PAVmed from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

In other news, CFO Dennis M. Mcgrath acquired 6,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of $4.21 per share, for a total transaction of $25,260.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have bought a total of 13,950 shares of company stock worth $57,653 over the last 90 days. Insiders own 79.30% of the company’s stock.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.